GLSI — Greenwich LifeSciences, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1799788 ·
Last close
$23.41
Market Cap
$343.62M
52W High
$30.26
52W Low
$20.53
ADV30
142,117
Next earnings
2026-08-13
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -5,725,754 | -5,657,137 | 10,505,435 | 10,505,435 | 5,235,229 |
| Dec 2025 | 0 | — | -7,944,991 | -7,922,733 | 6,178,021 | 6,178,021 | 5,824,804 |
| Sep 2025 | 0 | — | -4,174,642 | -4,151,845 | 3,806,978 | 3,806,978 | 1,622,001 |
| Jun 2025 | 0 | — | -4,045,953 | -4,025,278 | 3,125,101 | 3,125,101 | 1,685,609 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-12,781,497
Investing CF
—
Financing CF
$20,536,973
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.20
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-92,794,143
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-21,891,340
Pretax Income TTM
$-21,756,993
Interest Exp TTM
—
Analysts
2
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -19,447,918 | -19,358,218 | 6,178,021 | 5,824,804 | — | -9,913,453 |
| Dec 2024 | 0 | -16,011,817 | -15,788,809 | 4,093,769 | 1,559,733 | — | -7,266,543 |
| Dec 2023 | 0 | -9,327,866 | -8,891,803 | 6,994,815 | 294,406 | — | -6,478,602 |
| Dec 2022 | 0 | -8,040,254 | -7,825,237 | 13,477,029 | 262,905 | — | -6,200,027 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.82
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AVIR | Atea Pharmaceuticals, Inc. | $348.12M | $4.35 | — |
| VSTM | Verastem, Inc. | $351.49M | $4.00 | — |
| CATX | Perspective Therapeutics, Inc. | $335.30M | $2.94 | — |
| NATR | NATURES SUNSHINE PRODUCTS INC | $352.40M | $20.04 | — |
| VNDA | Vanda Pharmaceuticals Inc. | $353.60M | $5.88 | — |
News headlines (Yahoo Finance, 1h cache)
Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at ASCO Meeting 2026
2026-06-01 12:15 · Yahoo
GLSI Stock Climbs After Removing A Key Overhang – Retail Turns Focus To High-Stakes Breast Cancer Trial
2026-06-01 11:48 · Yahoo
Greenwich LifeSciences Provides Update Regarding Form 10-K Filing
2026-06-01 10:00 · Yahoo
Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing
2026-05-22 20:30 · Yahoo
Greenwich LifeSciences Announces Acceptance of Abstract at ASCO 2026
2026-04-23 10:00 · Yahoo
Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at AACR Meeting 2026
2026-04-20 10:00 · Yahoo
Greenwich LifeSciences Provides Update on Financing Strategy
2026-04-14 10:00 · Yahoo
Greenwich LifeSciences Provides Update on Patent Claims Potentially Doubling GP2 Market Potential
2026-04-07 10:00 · Yahoo
Greenwich LifeSciences Announces Addition of City of Hope to FLAMINGO-01
2026-03-19 10:00 · Yahoo
Greenwich LifeSciences Provides Update on Upcoming AACR Meeting
2026-03-18 10:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.